No Cover Image

Journal article 535 views 80 downloads

Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials

Vanita R. Aroda, Matthew S. Capehorn, Louis Chaykin, Juan P. Frias, Nanna L. Lausvig, Stanislava Macura, Jörg Lüdemann, Sten Madsbad, Julio Rosenstock, Omur Tabak, Sayeh Tadayon, Steve Bain Orcid Logo

Diabetes, Obesity and Metabolism, Volume: 22, Issue: 3, Pages: 303 - 314

Swansea University Author: Steve Bain Orcid Logo

Check full text

DOI (Published version): 10.1111/dom.13896

Published in: Diabetes, Obesity and Metabolism
ISSN: 1462-8902 1463-1326
Published: Wiley 2020
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa52246
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2019-10-02T14:22:46Z
last_indexed 2023-01-11T14:29:18Z
id cronfa52246
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-12-02T18:51:04.3450796</datestamp><bib-version>v2</bib-version><id>52246</id><entry>2019-10-02</entry><title>Impact of baseline characteristics and beta&#x2010;cell function on the efficacy and safety of subcutaneous once&#x2010;weekly semaglutide: A patient&#x2010;level, pooled analysis of the SUSTAIN 1&#x2010;5 trials</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2019-10-02</date><deptcode>BMS</deptcode><abstract/><type>Journal Article</type><journal>Diabetes, Obesity and Metabolism</journal><volume>22</volume><journalNumber>3</journalNumber><paginationStart>303</paginationStart><paginationEnd>314</paginationEnd><publisher>Wiley</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1462-8902</issnPrint><issnElectronic>1463-1326</issnElectronic><keywords/><publishedDay>1</publishedDay><publishedMonth>3</publishedMonth><publishedYear>2020</publishedYear><publishedDate>2020-03-01</publishedDate><doi>10.1111/dom.13896</doi><url>http://dx.doi.org/10.1111/dom.13896</url><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders/><projectreference/><lastEdited>2022-12-02T18:51:04.3450796</lastEdited><Created>2019-10-02T12:47:01.9834166</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Vanita R.</firstname><surname>Aroda</surname><order>1</order></author><author><firstname>Matthew S.</firstname><surname>Capehorn</surname><order>2</order></author><author><firstname>Louis</firstname><surname>Chaykin</surname><order>3</order></author><author><firstname>Juan P.</firstname><surname>Frias</surname><order>4</order></author><author><firstname>Nanna L.</firstname><surname>Lausvig</surname><order>5</order></author><author><firstname>Stanislava</firstname><surname>Macura</surname><order>6</order></author><author><firstname>J&#xF6;rg</firstname><surname>L&#xFC;demann</surname><order>7</order></author><author><firstname>Sten</firstname><surname>Madsbad</surname><order>8</order></author><author><firstname>Julio</firstname><surname>Rosenstock</surname><order>9</order></author><author><firstname>Omur</firstname><surname>Tabak</surname><order>10</order></author><author><firstname>Sayeh</firstname><surname>Tadayon</surname><order>11</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>12</order></author></authors><documents><document><filename>0052246-02102019125616.pdf</filename><originalFilename>Aroda2019.pdf</originalFilename><uploaded>2019-10-02T12:56:16.4030000</uploaded><type>Output</type><contentLength>382588</contentLength><contentType>application/pdf</contentType><version>Accepted Manuscript</version><cronfaStatus>true</cronfaStatus><embargoDate>2020-10-13T00:00:00.0000000</embargoDate><copyrightCorrect>true</copyrightCorrect><language>eng</language></document></documents><OutputDurs/></rfc1807>
spelling 2022-12-02T18:51:04.3450796 v2 52246 2019-10-02 Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2019-10-02 BMS Journal Article Diabetes, Obesity and Metabolism 22 3 303 314 Wiley 1462-8902 1463-1326 1 3 2020 2020-03-01 10.1111/dom.13896 http://dx.doi.org/10.1111/dom.13896 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2022-12-02T18:51:04.3450796 2019-10-02T12:47:01.9834166 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Vanita R. Aroda 1 Matthew S. Capehorn 2 Louis Chaykin 3 Juan P. Frias 4 Nanna L. Lausvig 5 Stanislava Macura 6 Jörg Lüdemann 7 Sten Madsbad 8 Julio Rosenstock 9 Omur Tabak 10 Sayeh Tadayon 11 Steve Bain 0000-0001-8519-4964 12 0052246-02102019125616.pdf Aroda2019.pdf 2019-10-02T12:56:16.4030000 Output 382588 application/pdf Accepted Manuscript true 2020-10-13T00:00:00.0000000 true eng
title Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials
spellingShingle Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials
Steve Bain
title_short Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials
title_full Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials
title_fullStr Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials
title_full_unstemmed Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials
title_sort Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
author Steve Bain
author2 Vanita R. Aroda
Matthew S. Capehorn
Louis Chaykin
Juan P. Frias
Nanna L. Lausvig
Stanislava Macura
Jörg Lüdemann
Sten Madsbad
Julio Rosenstock
Omur Tabak
Sayeh Tadayon
Steve Bain
format Journal article
container_title Diabetes, Obesity and Metabolism
container_volume 22
container_issue 3
container_start_page 303
publishDate 2020
institution Swansea University
issn 1462-8902
1463-1326
doi_str_mv 10.1111/dom.13896
publisher Wiley
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
url http://dx.doi.org/10.1111/dom.13896
document_store_str 1
active_str 0
published_date 2020-03-01T04:04:31Z
_version_ 1763753350680018944
score 11.016235

Similar Items